Astria Therapeutics (NASDAQ:ATXS) Posts Earnings Results, Beats Estimates By $0.01 EPS

Astria Therapeutics (NASDAQ:ATXS) released its quarterly earnings data on Tuesday. The biotechnology company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01, Zacks reports.

Astria Therapeutics Price Performance

Shares of ATXS stock traded up $0.01 during trading hours on Tuesday, hitting $5.83. 20,583 shares of the company’s stock were exchanged, compared to its average volume of 258,663. Astria Therapeutics has a 52 week low of $5.75 and a 52 week high of $16.90. The stock has a market cap of $329.01 million, a price-to-earnings ratio of -2.79 and a beta of 0.69. The stock’s 50-day moving average is $7.32 and its 200-day moving average is $9.65.

Analyst Upgrades and Downgrades

ATXS has been the subject of a number of analyst reports. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Oppenheimer raised their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Thursday, February 27th. Finally, JMP Securities initiated coverage on Astria Therapeutics in a report on Friday, January 31st. They set an “outperform” rating and a $26.00 price objective for the company. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $25.67.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.